1. Introduction
===============

Brown adipose tissue (BAT) in mammals helps to maintain body temperature during prolonged exposure to cold temperature by generating heat using energy in the body. This extraordinary metabolic capacity has the potential of regulating body fat stores and holds promise in combating obesity and diabetes \[[@r1]-[@r3]\]. Mitochondria in the brown adipocytes express uncoupling protein-1 (UCP1) which uses lipids and carbohydrates to generate heat by uncoupling electron transport from oxidative phosphorylation \[[@r4]\]. Activation of brown adipocytes results in unrestrained oxidation by drawing lipids and carbohydrates from outside the cell \[[@r5]\]. The role of BAT in understanding the mechanism of insulin sensitivity \[[@r6]\], lowering adiposity and improving type-2 diabetes \[[@r7]\], are being pursued and therefore make it a valuable target to study pathogenicity of obesity and diabetes.

Norepinephrine contained in neuronal fibers in BAT interact with β3 adrenoceptors (β3AR) present in the adipocyte cell surface \[[@r8]\]. This results in an increase in cyclic AMP (cAMP) which subsequently results in overexpression of UCP1 resulting in the enhancement of glycolysis \[[@r9]\]. Thus, agonist-mediated activation of β3AR on brown adipocytes has been evaluated as a strategy for studying BAT biology, and as a potential therapeutic approach for diabetes and obesity. Studies on presynaptic proteins which can elevate norepinephrine levels (*e.g.* norepinephrine transporter, NET) or at the level of secondary messenger changes (*e.g.* adenylyl cyclase) and peroxisome proliferator-activated receptor-γ (PPAR-γ) are limited and less understood. Other potential modulating factors of UCP1 levels have been recently reviewed \[[@r10]\].

Due to the growing incidence of obesity and diabetes globally, studies on BAT across different species are being pursued with great urgency. Several recent reviews have evaluated the potential role of BAT in energy use. These reviews have summarized the various approaches of imaging BAT and their shortcomings \[[@r11]\]. Other reviews have pointed to the value of diet-induced thermogenesis \[[@r12]\]. More recently, pharmacological strategies for BAT recruitment have been reported as a target of obesity and insulin sensitivity \[[@r13], [@r14]\].

We have previously reported several studies on drug-induced BAT activation \[[@r15]\]. This review summarizes our findings on BAT activation by various drugs used in the experimental and therapeutic approaches along with other published findings. It is by no means exhaustive, and at the time of writing this review, there were more than 9000 citations on "brown adipose tissue" in Pubmed and over 2200 occurred in the last 5 years.

2. Cold-induced BAT activation
==============================

Thermogenesis has been known for several decades and various studies have been reported on increased metabolic activity of BAT. Assessing the potential of BAT received an impetus from resolving the uptake of 2-deoxy-2-^18^F-fluoro-D-glucose (^18^F-FDG) in human BAT positron emission tomography/computed tomography (PET/CT) studies \[[@r16]-[@r18]\]. Around this time, BAT was visualized in rats using ^123^I-MIBG, an analog of norepinephrine \[[@r19]\], and more recently, norepinephrine transporters were visualized in BAT using ^11^C-MRB and ^11^C-TAZA \[[@r20], [@r21]\]. Additional studies have also included the use of ^11^C-acetate, ^11^C-palmitate and radiolabeled fatty acids as metabolic substrates \[[@r22], [@r23]\]. Measuring metabolic activity of BAT and assessing factors that influence BAT activity are important for the development of novel strategies in the regulation of body weight. BAT is active when its thermogenic function is stimulated \[[@r24]\], and accumulation of metabolic substrates such as ^18^F-FDG, ^11^C-acetate and ^11^C-palmitate is a consequence of UCP1 activity \[[@r9]\]. Activated BAT may thus have therapeutic potential to combat both diabetes and obesity with its ability to reduce plasma triglyceride levels \[[@r25]\]. The well-established literature of BAT biology in humans and animal models is now supported by quantitative analysis of ^18^F-FDG PET/CT imaging data \[[@r15], [@r27]-[@r29]\].

Cold temperatures increase ^18^F-FDG uptake in activated rodent BAT \[[@r30]\], and studies have been performed in both humans (\~16 ^o^C) \[[@r31]\] and rodents (\~4 ^o^C) \[[@r28]\], with some degree of success in demonstrating BAT activation \[[@r26]\]. Long-time exposure to cold temperature prior to PET was the only method until recently to study BAT in humans\--a function mediated by the β-adrenergic system \[[@r31]\]. The BAT prevalence from these studies ranged from 30% to 95%, which is higher than those of the retrospective studies \[[@r26], [@r31], [@r32]\].

3. Drug-Induced BAT Activation
==============================

In order to activate BAT at ambient temperatures, several pharmacological agents have been reported \[[@r27], [@r33]-[@r35]\] and some of these findings have been reviewed recently \[[@r13], [@r14], [@r36]\]. In this review, the various experimental and therapeutic drugs used for BAT related studies have been divided into 4 major classes. The classification is primarily based on the most probable site of action of the drugs. Fig. (**[1](#F1){ref-type="fig"}**) depicts classification of the drugs based on their site of action. Class 1 drugs are the β3AR agonists which act on the β3AR located on the adipocyte cell surface. These drugs have been used in animal and human studies. Class 2 consists of drugs that have an effect on altering the norepinephrine levels or directly mimicking norepinephrine effect or by blocking the norepinephrine transporter (NET) located on the sympathetic nerve terminal. Class 3 drugs are activators of peroxisome proliferator-activated receptor-γ (PPAR-γ) and act within the adipocyte. Class 4 are other drugs including natural products on which information is limited or is now emerging.

3.1. Class 1 Drugs: β3 Adrenoceptor Agonists
--------------------------------------------

Agonists for β3AR are currently used clinically for overactive bladder (OAB) \[[@r37]\]. The β3AR are G-protein coupled receptors (GPCR) and are found in significant levels on brown adipocytes \[[@r38]-[@r41]\]. BAT is innervated by sympathetic nerves containing norepinephrine which activate β3AR. A significant effort has been made to evaluate β3AR selective agonists as possible therapeutic agents for the treatment of obesity \[[@r42]\].

Table **[1](#T1){ref-type="table"}** shows a list of β3AR selective agonists which are derivatives of the "2-hydroxyethylamino" backbone mimicking norepinephrine. BRL 37344, an active metabolite of BRL 35135 is known to be selective for adipocyte lipolytic response \[[@r43]\]. Furthermore, 2-deoxy-\[^3^H\]-glucose has been used to investigate glucose utilization index (GUI) of BRL-35135. It has been shown that chronic treatment with BRL 37344 causes a 34 fold increase in basal GUI of BAT with no effect on GUI of other tissues \[[@r44]\]. BRL 35135 was also effective in improving glucose tolerance in genetically obese (ob/ob) mice and obese Zucker (fa/fa) rats at doses that had no significant anti-obesity activity \[[@r45]\].

CL316,243, (*R*,*R*)-5-\[[@r2]-\[[@r2],3-(3-chlorphenyl)-2-hydroxy-ethyl-amino\]propyl\]-1,3-benzodioxole-2,2-dicarboxylate, di-sodium salt is a β3AR selective agonist \[[@r34],[@r46]\]. CL316,243 activated interscapular BAT (IBAT), cervical, periaortic and intercostal BAT, which were clearly visualized by PET (Fig. **[2](#F2){ref-type="fig"}**) \[[@r29]\]. Because of the selective nature of CL316,243, it may be inferred that the increase in ^18^F-FDG uptake occurred due to stimulation of the β3AR. This is consistent with the reported effects of CL316,243 on overall energy expenditure in BAT \[[@r33]\]. CL316,243 promotes BAT mitochondrial proliferation and energy expenditure in brown fat is capable of ranging over many orders of magnitude, controlled primarily by sympathetic stimulation mediated by rapid changes in UCP1 intrinsic activity \[[@r47]\]. In initial human studies with CL316,243 energy expenditure after 8 weeks in young lean males did not differ from baseline \[[@r48]\]. Human studies using CL316,243 were discontinued due to poor bioavailability of the drug.

Three closely related derivatives, rafabegron, mirabegron and solabegron are being pursued for clinical use in OAB and irritable bowel syndrome (IBS) \[[@r37]\]. Rafabegron exhibited some increase (\~50 kcal/ day) in 24-h energy expenditure (EE) at highest dose in obese men and women \[[@r49]\]. Solabegron which is being pursued for IBS has not been studied for effects on EE. Mirabegron, a β3AR selective agonist \[[@r50]\] is approved for use in OAB \[[@r51]\]. Mirabegron was shown to activate rat \[[@r52]\] IBAT and human \[[@r53]\] BAT metabolic activity as measured by ^18^F-FDG PET/CT. Thus, mirabegron-induced increased glucose metabolism in BAT across species is of potential interest for obesity and diabetes.

ZD2079 (talibegron) and ZD7114 are selective β3AR drugs which increase EE *via* non-shivering and reduced weight gain and activated thermogenesis \[[@r54]\]. ZD7114 also has been reported to have antagonist properties at β3AR in isolated rat ileum \[[@r55]\]. ZD7114 had no effect on 24 h EE in obese women and men, while ZD2079 had a very small stimulatory effect on EE \[[@r56]\]. Their value is for weight loss or diabetes is therefore questionable. The structurally similar ICID7114 has been reported to stimulate BAT and oxygen consumption in canine studies \[[@r57], [@r58]\]. However, no further reports on its effects on weight loss or diabetes have appeared. In the case of the somewhat larger molecule, L-796568, after a 28-day treatment with L-796568 in nondiabetic men no major effect was observed on lipolytic or thermogenic measures \[[@r59]\].

Other clinically used β3AR agonists, amibegron (SR 58611A) \[[@r60], [@r61]\] have been pursued as antidepressants in clinical trials, but have now been discontinued. β3 adrenoceptors are mostly found in BAT, white adipose tissue, myocardium, skeletal muscle, and liver \[[@r40], [@r62]\]. Expression of β3 adrenoceptor mRNA in the brain is lower than in BAT \[[@r63]\]. It is unclear if the low brain concentration of β3AR affected the poor outcome with amibegron.

3.2. Class 2 Drugs: Norepinephrine Altering Drugs
-------------------------------------------------

Norepinephrine activates β3AR and cold temperatures may promote metabolism indirectly by elevating norepinephrine levels \[[@r64], [@r65]\]. Uptake of 2-\[^3^H\]-DG (glucose metabolic index) in BAT was elevated with increasing doses of norepinephrine \[[@r66]\]. Thus, the capacity of BAT thermogenesis is increased with norepinephrine \[[@r67]\]. In UCP1 ablated mice, addition of norepinephrine in brown adipocytes resulted in no increase in oxygen consumption rate. It has been shown that BAT activity increases with ephedrine (structurally related to norepinephrine, Table **[2](#T2){ref-type="table"}**) in lean but not in obese participants. The change in BAT activity after ephedrine compared with placebo was negatively correlated with various indices of body fatness \[[@r68]\]. Chronic ephedrine treatment reduced body fat content, but this was not associated with an increase in BAT activity; chronic ephedrine suppressed BAT glucose disposal, suggesting that treatment decreased, rather than increased, BAT activity \[[@r69]\].

Atomoxetine is a potent and highly selective blocker of presynaptic NET that is used for treatment of attention deficit hyperactivity disorder (ADHD) \[[@r70]\]. Atomoxetine leads to increased synapse concentrations of norepinephrine and therefore an increase in adrenergic neurotransmission \[[@r71]\]. Uptake of a highly selective NET ligand, ^11^C-MRB, suggests the existence of these transporters in BAT \[[@r20]\]. Uptake of ^11^C-TAZA *via* the NET in the IBAT as well as other BAT regions was also very evident as can be seen in the Supplementary (Fig. **[1](#F1){ref-type="fig"}**) using PET \[[@r21]\]. Atomoxetine effects on BAT metabolism in rats were quantified by ^18^F-FDG PET and have recently been reported \[[@r72]\]. This increase is substantially higher than that of ephedrine \[[@r27]\]. Propranolol inhibited atomoxetine-induced BAT activation to control levels and confirmed the likelihood of action of atomoxetine *via* the β3AR. There are few reports introducing atomoxetine as a weight loss agent. A preliminary study to evaluate short-term anti-obesity efficacy demonstrated modest short-term weight loss in obese women \[[@r73]\]. In a trial on outpatients with binge-eating disorder, atomoxetine was found to be efficacious \[[@r74]\]. However, it was not effective for weight loss in those who have gained weight on either clozapine or olanzapine \[[@r75]\].

Nisoxetine, another potent and selective inhibitor of NET uptake was shown to bind IBAT \[[@r76]\]. Increased IBAT binding density from angiotensin II infusion led to promising results of body weight reduction due to increased sympathetic neurotransmission \[[@r77]\]. Sibutramine another NET reuptake inhibitor exhibited thermogenic effects but had cardiovascular side effects \[[@r78]\]. Fibromyalgia patients on another NET reuptake inhibitor, milnacipram showed an approximately 5% weight loss in 3-6 months \[[@r79]\].

3.3. Class 3 Drugs. PPAR-γ Activators
-------------------------------------

Activation of PPARγ by the glitazone class of drugs (also referred as thiazolidinediones) affects carbohydrate and lipid metabolism by several mechanisms and have been pusued for type 2 diabetes \[[@r80]\]. Given the role of brown adipocytes in the enhancement of energy expenditure, promotion of brown fat adipogenesis by thiazolidinediones could contribute to the beneficial effects of these drugs on insulin sensitivity in humans. Table **[3](#T3){ref-type="table"}** shows the structural similarities of the thiazolidinediones.

Rosiglitazone (BRL-49653), has been shown to promote differentiation of the brown pre-adipocyte cell line and to increase rat IBAT mass. Rosiglitazone treatment of human pre-adipocytes prepared from all depots resulted in increased levels of UCP1 mRNA \[[@r81]\]. Previous studies have shown that rodents treated with high doses of troglitazone, another type of thiazolidinedione, increased IBAT \[[@r82]\].

Ciglitazone decreased blood glucose, triglycerides, and food intake without affecting body weight in obese hyperglycemic mice. It did show a decrease in human blood sugar but is not currently used in any medication form \[[@r83]\]. Trogli-tazone improves GLUT4 expression in obese type 2 diabetic rat model and increases insulin sensitivity in non-insulin-dependent diabetes mellitus but with serious liver side effects \[[@r84]\]. It was used as an anti-diabetic, but has now been discontinued. Pioglitazone is currently used to treat diabetes mellitus and has urinary bladder side-effects in some cases \[[@r85],[@r86]\]. It has been shown to play a role in remodeling of adipocytes in the rat model \[[@r87]\]. Balaglitazone lowered glucose levels and did not affect fluid retention or bone formation in obese rats. It had effects on blood glucose levels and HbA1c in type 2 diabetes patients \[[@r85], [@r86]\]. Rivaglitazone also lowers glucose levels by improving insulin sensitivity in diabetic animal models. Improved glycemic control in type 2 diabetic patients short time. Rivoglitazone is undergoing trials in treatment of type 2 diabetes mellitus to asses potential health risks with this drug \[[@r87], [@r88]\]. Darglitazone exhibited an increase in BAT with altered morphology in rats \[[@r89]\]. Clinical development of darglitazone has been discontinued.

Thus, pioglitazone is currently the most promising agent in this class of drugs. Although blood sugar has been lowered by pioglitazone, its ability to induce browning of adipocytes and assist in weight loss has yet to be demonstrated, No PET imaging studies to study BAT activation (either animal or human) using pioglitazone have been reported. It may be useful to evaluate if BAT is activated *in vivo* using pioglitazone and compare these findings with those of mirabegron from class 1 drugs.

3.4. Class 4 Drugs. Other Products/Natural Products
---------------------------------------------------

Intraperitoneal injection of nicotine causes the release of catecholamines, including norepinephrine, which stimulates thermogenesis in BAT for energy expenditure \[[@r90]\]. Nicotine causes increases in ^18^F-FDG uptake in BAT, and the effect is further enhanced when nicotine is combined with ephedrine \[[@r27]\]. These results suggest that nicotine stimulates norepinephrine turnover and BAT thermogenesis while also promoting resting metabolic rate, all of which contribute to the mitigation of obesity \[[@r91]\].

Forskolin is known as an inducer of thermogenic response in BAT \[[@r92]\]. It activates the adenylyl cyclase enzyme directly and increases the intracellular levels of camp \[[@r93]\]. Thus, forskolin is capable of enhancing BAT metabolism as measured by ^18^F-FDG PET/CT \[[@r15]\].

Caffeine significantly elevated BAT temperature with less effect on core temperature, and oxygen consumption in BAT mitochondria suggesting caffeine activates BAT thermogenesis \[[@r94]\]. Adenosine receptors, A2A have been suggested to play a role in BAT activation \[[@r95]\]. It remains to be demonstrated if interaction of caffeine with adenosine receptors plays a role on its effects on BAT.

Previous studies have shown a significant reduction in adiposity after prolonged ingestion of capsinoids (capsacin) in humans. BAT is involved in the capsinoid-induced increase in energy expenditure, as presented in small rodents. Increased UCP1 expression was also shown in rats treated with capsinoids for 2 weeks \[[@r96]\]. Capsinoid ingestion increases energy expenditure through the activation of brown adipose tissue in humans \[[@r97]\].

Curcumin is a yellow pigment found in turmeric and has been investigated as a treatment for obesity-related diseases. It interacts directly with adipocytes, pancreatic cells, hepatic stellate cells, macrophages, and muscle cells. Curcumin has been used to reverse insulin sensitivity, hyperglycemia, hyperlipidemia, and other symptoms linked to obesity. It also has the capability of binding to PPAR-γ in order to stimulate differentiation of human adipocytes \[[@r98]\]. It has been further demonstrated to improve cold tolerance in mice and to promote β3 adrenoceptor gene expression in inguinal WAT. Elevation of plasma norepinephrine levels were enhanced with curcumin treatment \[[@r99]\].

Rimonabant, a cannabinoid CB1 receptor drug caused weight loss which was thought to due to elevated BAT temperature mediated by the peripheral endocannbinoid system which was confirmed by the peripheral CB1 receptor antagonist AM6545 \[[@r100], [@r101]\]. However, rimonabant has been withdrawn from the market due to side effects \[[@r102]\]. Use of peripherally acting CB1 receptor drugs, such as AM6545 in PET imaging may be useful for further evaluation of the role of this target receptor.

ShK-186, a selective Kv1.3 peptide inhibitor, exhibits robust therapeutic effects in a mouse model of diet-induced obesity and insulin sensitivity \[[@r103]\]. ShK-186 activated BAT as evidenced by increased glucose uptake, enhanced β-oxidation, and elevated transcription of the UCP1 gene involved in BAT thermogenesis. In mice fed an obesity-inducing diet, ShK-186 reduced weight gain despite voracious calorie consumption. These beneficial changes may be associated with elevated membrane remodeling and a simultaneous increase in PPARγ expression and the metabolites that activate PPARγ. Since PPARγ agonists improve insulin sensitivity and diabetes control \[[@r104]\], enhanced PPARγ signaling in ShK-186-treated mice may contribute to the peptide's therapeutic effects.

4. Therapeutic Potential
========================

4.1. Class 1 Drugs
------------------

The presence of β3AR in human BAT allows for a targeted therapeutic strategy \[[@r62]\]. However, concerns such as selectivity and bioavailability of the drugs as well as measureable effects on weight loss have yet to be fully understood for class I drugs. CL 316,243 has only a 10-fold selectivity for human β3 over β2 adrenoceptor and β3AR mRNA is also expressed in the human heart \[[@r105]\], which increases the concerns regarding its cardiovascular side effects. However, CL 316,243 has not been reported to affect heart rate, systolic and/or diastolic blood pressures, ECG intervals or to cause development of tremors \[[@r48]\]. Newer drugs such as mirabegron, targeting this receptor have now been approved for clinical use in OAB but their potential for the treatment of type 2 diabetes has yet to be established \[[@r39]\].

Chronic CL316,243 administration has been shown to have an anti-obesity effect in mice and rats \[[@r33],[@r106],[@r107]\]. Quantitative analysis of ^18^F-FDG uptake in rats treated with CL316,243 has provided evidence on the ability of acute β3AR stimulation by CL316,243 to increase BAT metabolism *in vivo* using PET. In the early stages of exposure to cold temperatures, mobilization of fatty acids from WAT is also known to be a primary source for activation of BAT rather than the breakdown of fat depot stored in BAT \[[@r108],[@r109]\]. Our histology studies showed that the number of lipid vacuoles in BAT was substantially decreased after stimulation by CL316,243, while there was no significant change in WAT lipid content between the two conditions \[[@r29]\]. Therefore, in acute administration of CL316,243, glucose metabolism and lipolysis of stored lipids in BAT are primary sources for activation of the tissue rather than the mobilization of fatty acids from WAT. Although its *in vitro* binding to the human β3AR is similar to that of the rodent receptor, it is only a partial (60%) agonist at the human β3AR ---in contrast to the rodent receptor, where CL 316,243 is a full agonist--- and its bioavailability is poor, with \~10% of an oral dose being absorbed \[[@r48]\].

β3 adrenoceptor agonist mediated BAT activation using ^18^F-FDG PET/CT has been investigated in Zucker lean (ZL) and obese (ZF) rats. Brain ^18^F-FDG PET studies in the ZF model have been reported to study the central effects of leptin-receptor deficiency \[[@r110],[@r111]\]. CL316,243 activated BAT in ZL up by 4-fold and in ZF up by two-fold compared to saline \[[@r112]\]. The decreased activation was consistent with lower β3 adrenoceptor levels in ZF rats \[[@r113]\]. Despite the lower β3 adrenoceptor levels and reduced G-protein coupling in the ZF rat model, the agonist CL316,243 showed some measureable effects on BAT. The CT scans showed a significantly low opacity in ZF compared to ZL, suggesting low abundance of brown adipocytes in the IBAT region. There is renewed focus on the development of therapeutics to restore leptin receptor function in order to address human obesity \[[@r114]\]. Thus, the leptin-receptor deficient *fa/fa* rat model demonstrates that the residual β3AR conserved in this rat model are functional with respect to enhancing metabolic activity. In addition, the coupling of the β3AR with the G-protein is reportedly reduced in white adipocytes \[[@r115]\]. Abnormalities in central metabolism regulation and neuroendocrine metabolism may also contribute to BAT thermogenesis impairment \[[@r113]\]. Chronic β3AR drug treatment studies of this rat model may be of value to study restoration of brown adipocytes.

In an early study done on type 1 diabetes mellitus (TIDM) streptozotocin-treated rat model, results show that the metabolic capacity of IBAT in streptozotocin-diabetic rats is decreased \[[@r116]\]. Our recent findings confirmed the loss of metabolic activity in streptozotocin-diabetic rats \[[@r117]\]. Comparing the two diabetic models, it appears that the reduction in IBAT activity in the Zucker fat rat may be driven by impaired β3AR signaling, whereas for the reduction in the streptozotocin-treated rats, the impairment may be driven by mitochondrial dysfunction. Our results also suggest that IBAT is activated by stimulation of β3AR in this T1DM rat model and is able to enhance metabolic activity. However, attempts to alter norepinephrine levels using atomoxetine had little effect, possibly due to impaired norepinephrine turnover. Blockage of the insulin receptors in BAT transplant streptozotocin-treated mice lead to impaired glucose tolerance, similar to what is seen in nondiabetic animals, indicating that insulin receptor activity plays a role in reversing diabetes \[[@r118]\].

Since mirabegron is a selective β3AR agonist in clinical use for OAB, studies in diabetes rodent models as described above may be worthwhile. Compared to CL316,243, mirabegron has better agonist potency for human β3AR \[[@r29], [@r51]\]. Amibegron is another selective β3AR agonist that crosses the BBB and has anti-depressant like properties such as its ability to increase serotonin synthesis \[[@r61]\]. Thus, further studies are warranted on the various disease models using the newer, human translatable β3AR drugs.

4.2. Class 2 Drugs
------------------

Atomoxetine is a selective norepinephrine reuptake inhibitor and has low abuse potential \[[@r70]\]. Atomoxetine, structurally related to the antidepressant fluoxetine acts by elevating synaptic norepinephrine levels with few side effects \[[@r119], [@r120]\]. Cardiovascular side effects in adult placebo-controlled trials showed increased heart rate (3.0%) and increased blood pressure \[[@r121], [@r122]\]. It has been used in psychiatry for the treatment of both adult and pediatric ADHD, with relatively benign side effects \[[@r123], [@r124]\]. Under fasting conditions, atomoxetine initiated extensive ^18^F-FDG increase in BAT compared to control rats \[[@r72]\].

BAT in patients with pheochromocytoma (excess release of epinephrine and norepinephrine from adrenal gland) has been reported to exhibit very intense ^18^F-FDG uptake \[[@r125], [@r126]\]. Due to the adrenergic interaction with β1 and β2 adrenoceptors serious cardiovascular side effects were noted in in these patients \[[@r127]\]. Thus, any potential adrenergic agonist for BAT activation should be highly specific for β3AR.

Sibutramine is a combined norepinephrine and serotonin reuptake inhibitor. It is used as an anti-obesity agent to reduce appetite and promote weight loss in combination with diet and exercise. It improves insulin sensitivity and glucose metabolism; however it is believed that most of these effects result from weight loss rather than from an intrinsic effect of the drug \[[@r128]\]. Milnacipran is another serotonin-norepine-phrine reuptake inhibitor anti-depressant. It has been used in co-morbid depression which is common in patients with diabetes mellitus. It improves blood glucose and HbA1c levels in type 2 diabetics. It is suggested that the effective treatment of depression results in higher sense of self-care which leads to improvement in the metabolic parameters \[[@r129]\], and BAT activation is protective against hyperglycemia \[[@r130]\].

4.3. Class 3 Drugs
------------------

Of the many thiazolididiones investigated as agents affecting adipogenesis \[[@r131], [@r132]\] serious side effects have hampered studies in humans in order to investigate BAT activation \[[@r13], [@r80]\]. Pioglitazone is currently the one PPARγ activator used for type 2 diabetes \[[@r133]\]. A recent study includes pioglitazone in a India-specific algorithm for management of type 2 diabetes \[[@r134]\]. The role of BAT in the glucose lowering effect of pioglitazone remains to be demonstrated, since UCP1 in human epicardial adipose tissue remained unaltered after pioglitazone treatment \[[@r135]\]. Thus, thermogenic effect of thiazolidinones *via* PPARγ remains to be demonstrated \[[@r136]\]. Measurements of the effect of pioglitazone on animal or human BAT using ^18^F-FDG imaging methodology would be useful to confirm increased metabolic activity.

4.4. Class 4 Drugs
------------------

Nicotine has been shown to activate BAT \[[@r137]\]. However, the effect on weight loss/gain associated with smoking has been attributed to the effect of nicotine in brain regions such as the hypothalamus \[[@r138]\]. Forskolin directly activates adenylyl cyclase and raises cAMP levels in a wide variety of cell types \[[@r139]\]. Forskolin increased BAT ^18^F-FDG SUV 1.6-fold compared to control mice \[[@r15]\]. On the other hand, forskolin increases heart myocardium ^18^F-FDG, with side effects including headaches, decreased blood pressure, and a rapid heart rate. It has inotropic and vasodilatory properties both *in vitro* and *in vivo*, and changes in contractility parallel an increase in cAMP concentration as well as calcium transport into the myocardium \[[@r140]\]. Evidence for a role of forskolin in weight loss in humans is limited \[[@r141]\]. Caffeine appears to have some small effects on increasing fat metabolism which is enhanced when used in combination with ephedra \[[@r141]\]. Anti-obesity effects of capsacin may occur through activation of brown and beige adipocytes \[[@r142], [@r143]\]. Curcumin has been shown to promote browning of white adipose tissue \[[@r144]\]. A bioavailable form of curcumin was recently shown to increase weight loss in overweight people with metabolic syndrome \[[@r145]\]. Interesting findings on the role of the cannabinoid receptor system in weight loss have been reported \[[@r146], [@r147]\]. Although rimonabant has CNS side effects, other agents targeting the peripheral receptor may have promise. ShK-186, a selective Kv1.3 peptide inhibitor, is undergoing clinical trials as a therapeutic for autoimmune diseases \[[@r148]\]. It exhibited robust therapeutic effects in a mouse model of diet-induced obesity and insulin sensitivity \[[@r103]\]. Fibroblast growth factor 21 (FGF21) has been the focus of recent studies for obesity and may have the ability, at least in part to activate BAT \[[@r149]\]. Recent reviews have focused on therapeutic potential of engineered FGF21 analogs \[[@r150]\].

4.5. BAT Transplantation
------------------------

Transplantation of BAT in obese subjects will be advantageous over pharmacological drug effects due to the significantly lower levels of BAT in the obese subjects. Several reports have been published and recent reviews have summarized their findings. Efforts have focused on BAT transplantation as a potential therapeutic tool for obesity by improving control over body composition and metabolism and were recently reviewed \[[@r151]\]. In order to overcome issues related to transplanting harvested BAT, tissue-engineering pathways, including stem cells to develop adipose tissue implants is currently underway in order to provide BAT for human therapeutic purposes \[[@r152], [@r153]\]. These pathways offer alternatives to pharmacological approaches or may be used in conjunction with pharmacological approaches in order to tackle obesity and diabetes.

5. Summary
==========

Currently, the prevalence of BAT in the adult population is reportedly low \[[@r154]-[@r157]\], which dampens its potential significance for altering adult human metabolism. BAT is only active when its thermogenic function is required or pharmacologically stimulated \[[@r24], [@r27]\], and ^18^F-FDG uptake is a direct consequence of tissue activity \[[@r9]\]. Thus, inactive BAT would not be visible on PET scans. Due to the potential role of BAT in obesity \[[@r158], [@r159]\] efforts towards pharmacological activation have increased \[[@r160], [@r161]\]. Pharmacologically induced brown adipocyte biogenesis along with engineered tissue transplantation is now possible thus raising the possibility for drug development in combating diabetes and obesity.
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![**Schematic of Sites of Drug Action**: Class 1 drugs act on the adipocyte cell membrane bound β3 adrenergic receptor (β3AR) triggering a cascade of events *via* cAMP. Class 2 drugs act on the norepinephrine transporter (NET) on the sympatheic nerve terminal and increase norepinephrine (NE) levels which then stimulates β3AR. Class 3 drugs activate peroxisome proliferator-activated receptor gamma (PPARγ). Class 4 drugs act on various pathways within the adipocyte. Abbreviations: AC: adenylate cyclase; Gs: stimulatory G-protein; ATP: adenosine triphosphate; cAMP: cyclic adenosine monophosphate; PKA: protein kinase A; TG: triglycerides; FFA: free fatty acids; UCP-1: uncoupling protein-1(found in mitochondria); Glu: glucose. Norepinephrine.](CDR-12-414_F1){#F1}

![**PET Images from Class 1 Drug Effects on Rat BAT**: CL316,243 induced activation of BAT is seen in the PET image (B) and regional localization confirmed by PET/CT (A). Interscapular, periaortic, cervical and intercostal BAT regions are evident. The bilateral structure of activated interscapular BAT (IBAT) is evident in the ventral (C), dorsal (D) and caudal (E) views of IBAT (Figure adapted from Mirbolooki *et al.*, 2011) \[[@r29]\].](CDR-12-414_F2){#F2}

![**Class 1 Drug Effects on Obesity and Type1 Diabetes Model**: Graph showing effects of CL316,243 (CL) in the two rodent models. In Zucker rat obese models (and T2DM), uptake of ^18^F-FDG in Zucker lean (ZL) increased by +231% with CL316,243 while Zucker fat (ZF) were reduced by -44% with little effect of CL316,243. In T1DM streptozotocin (STZ) model, uptake of ^18^F-FDG in Sprague-Dawley normal (SD Nor) increased by +624% with CL316,243, whereas SD STZ was reduced by -70%. An increased uptake of ^18^F-FDG was seen SD STZ upon CL316,243 treatment, suggesting some recovery of BAT function.](CDR-12-414_F3){#F3}
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Therapeutic Potential of BAT Activators.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Drug Class**                       **Observed Physiological**\                                 **Effect on Caloric Consumption;**\                                                                                         **Current Therapeutic Status**
                                       **Effects**                                                 **Weight Loss or Gain**                                                                                                     
  ------------------------------------ ----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  *Class 1*\                           Increase in BAT activation in animal and human studies.     Burns calories by consuming glucose. Weight loss in animals---no human data.\                                               *Mirabegron* used clinically in OAB. Use in IBS of related drugs being pursued. Use for weight loss unclear.
  Selective β3 Adrenoceptor Agonists                                                               Significant loss of β3AR activation in obese models. Chronic treatment studies needed to demonstrate regeneration of BAT.   

  *Class 2*\                           Lower blood glucose;\                                       Weight reduction shown in obese women.                                                                                      *Atomoxetine* used clinically for ADHD. Potential for small weight loss.
  Norepinephrine\                      Increase BAT activation and thermogenesis.                                                                                                                                              
  Elevators                                                                                                                                                                                                                    

  *Class 3*\                           Increased energy expenditure and improved cold tolerance.   Does not affect caloric intake.\                                                                                            *Pioglitazone* used clinically for T2DM. Other analogs have side effects and not used.
  PPAR-γ Activators                                                                                Pioglitazone shown to aid in weight loss.                                                                                   

  *Class 4*\                           Increased energy expenditure and UCP1 gene expression.      Increases fat metabolism and reduces weight gain.\                                                                          No clinically approved product for obesity or diabetes. *ShK-186* undergoing trials for MS.
  Natural and Other Products                                                                       ShK-186 reduced weight gain in DIO mice.                                                                                    
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